11/11/2024

23.4% Sodium Chloride Injection

Products Affected - Description

- 23.4% Sodium Chloride solution for injection, Fresenius Kabi, 100 mL 20 count, NDC 63323-0095-61
- 23.4% Sodium Chloride solution for injection, Fresenius Kabi, 200 mL vial, 20 count, NDC 63323-0099-63
- 23.4% Sodium Chloride solution for injection, Fresenius Kabi, 30 mL vial, 25 count, NDC 63323-0093-30
- 23.4% Sodium Chloride solution for injection, Pfizer, 100 mL bulk glass container, 25 count, NDC 00409-1141-02

Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer has 23.4% sodium chloride on shortage due to increased demand.

Available Products

- There is insufficient supply for usual ordering

Estimated Resupply Dates

- Fresenius Kabi has 23.4% sodium chloride 30 mL, 100 mL, and 200 mL vials on back order and the company estimates a release date of early- to mid-December 2024 for the 30 mL vials and mid- to late-November 2024 for the 100 mL and 200 mL vials.
- Pfizer has 23.4% sodium chloride 100 mL vials on back order and the company estimates a release date of December 2024.

Updated

Updated November 11, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created October 26, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.